Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial Evaluating Safety and Efficacy of Pembrolizumab and Cisplatin in Patients With Advanced Triple Negative Breast Cancer

NCT03644589 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03644589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03644589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial Evaluating Safety and Efficacy of Pembrolizumab and Cisplatin in Patients With Advanced Triple Negative Breast Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Withdrawn
Start date
April 1, 2019
Completion date
October 30, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor negative, her2/neu negative, metastatic breast cancer, progesterone receptor negative, recurrent breast carcinoma, triple negative breast cancer